Data Provided by Refinitiv. Minimum 15 minutes delayed.
January 5, 2022
December 20, 2021
CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71
November 11, 2021